亿帆医药: 关于在下属子公司之间调剂担保额度及为全资子公司提供担保的进展公告

Group 1 - The company has approved a total credit limit of up to RMB 650 million for itself and its subsidiaries, with a guarantee limit of RMB 600 million for companies within the consolidated scope [1][2] - The company has adjusted the unused guarantee limit of RMB 200 million from Hefei Yifan Pharmaceutical Co., Ltd. to Hefei Yifan Biopharmaceutical Co., Ltd., increasing the guarantee for the latter from RMB 900 million to RMB 1.1 billion [2] - The company has signed guarantee contracts with various banks, including a maximum guarantee amount of RMB 50 million with Agricultural Bank of China, RMB 60 million with Industrial and Commercial Bank of China, and RMB 200 million with Industrial Bank [3][4][5] Group 2 - The company has provided guarantees for its wholly-owned subsidiaries, Hefei Yifan Biopharmaceutical Co., Ltd. and Hefei Yifan Pharmaceutical Co., Ltd., to support their business development [18] - The total assets of Hefei Yifan Biopharmaceutical Co., Ltd. are reported at RMB 3.167 billion, with total liabilities of RMB 1.567 billion and net assets of RMB 1.600 billion [6] - The total assets of Hefei Yifan Pharmaceutical Co., Ltd. are reported at RMB 1.646 billion, with total liabilities of RMB 951.7 million and net assets of RMB 694.3 million [9] Group 3 - The company has confirmed that the financial risks associated with the guarantees are within controllable limits, and the guarantees comply with relevant regulations [18] - As of the report date, the cumulative external guarantee balance of the company and its subsidiaries is RMB 4.582 billion, accounting for 53.77% of the company's audited net assets for 2024 [18]